is novolog a glp-1 receptor agonists GLP-1 Medications for Weight Loss:

Patients who relied on compounded semaglutide are transitioning back to branded Ozempic, Wegovy, and Rybelsus

Causality has not been established, but these agents should be used cautiously in patients with a history of pancreatitisparticularly if the cause of the initial event is unknown

Lilly clearly possesses the more compelling pipeline on paper, with tirzepatide (Mounjaro/Zepbound) already showing superior weight loss compared to semaglutide, alongside additional next-gen candidates like oral orforglipron and triple-agonist retatrutide advancing through late-stage studies

This process may gradually shift the production of darker eumelanin toward lighter pheomelanin

According to a new Gallup survey, 11% of US adults now take GLP-1 drugs specifically for weight loss, up from 3% in 2024